Balloon-pump assisted Coronary Intervention Study BCIS-1 Simon Redwood Divaka Perera, Rod Stables, Martyn Thomas.

Slides:



Advertisements
Similar presentations
ACTION Registry (Acute Coronary Treatment and Intervention Outcomes Network) Initial Report 1st Quarter 2007 Results Report prepared by: www. ncdr.com.
Advertisements

A Prospective, Randomized Comparison of Paclitaxel-eluting TAXUS Stents vs. Bare Metal Stents During Primary Angioplasty in Acute Myocardial Infarction.
B alloon-pump assisted C oronary I ntervention S tudy BCIS-1 Simon Redwood Kings College London/ St Thomas Hospital Steering Committee: Divaka Perera,
Widimsky P, Tousek P, Rokyta R, et al. Charles University Prague, CZ PRAGUE-7 Study (Hot Lines presenter)
Introduction Recent guidelines considered PCI to be a potential alternative to CABG for ULMCA stenosis, based on several large registries and randomized.
Radial versus Femoral Randomized Investigation in ST Elevation Acute Coronary Syndrome the RIFLE STEACS study Enrico Romagnoli, MD PhD Principal investigators:
A few basics of cardiac surgery…. Brett Sheridan, MD Assistant Professor Department of Surgery.
CPORT- E Trial Randomized trial comparing medical, economic and quality of life outcomes of non-primary PCI at hospitals with and without on-site cardiac.
J. Mehilli, MD, G. Richard, F-J. Neumann, S. Massberg, K-L. Laugwitz, J. Pache, J. Hausleiter, I. Ott, M. Fusaro, T. Ibrahim, A. Schömig, A. Kastrati Deutsches.
Multivessel coronary disease diagnosed at the time of primary PCI for STEMI: complete revascularization versus conservative strategy. PRAGUE 13 trial O.
2 Year Clinical Outcomes from the Pivotal RESOLUTE US Study Laura Mauri MD, MSc on behalf of the RESOLUTE US Investigators Brigham and Women’s Hospital.
STEMI Due to Stent Thrombosis: An Enlarging Subgroup of High Risk Patients Bruce Brodie, Adam Bensimhon, Nathan Fleishman, Charles Hansen, Mike Cooper,
Raising the standard in treating bifurcation lesions GENNARO SARDELLA MD, FACC,FESC O.U. of Interventional Cardiology Dept. of.
ST-Elevation Myocardial Infarction & Cardiogenic Shock - What Should We Do? Advanced Angioplasty 2008 Dan Blackman Leeds General Infirmary.
COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)
Francesco Liistro Cardiovascular Department, Arezzo, Italy Impact of Thrombus Aspiration on Myocardial Tissue Reperfusion and Left Ventricular Functional.
Amr Hassan Mostafa, MD, FSCAI A. Professor of Cardiology Cairo University Cairo, Egypt Egypt Combat MI, March 24-25, Cairo Sheraton.
Around-the-Clock Primary Angioplasty: A Process of Care Analysis Comparing Off-Hours and Normal Hours Treatment of Acute STEMI R Leung, D Lundberg, D Galbraith,
Adnan Kastrati, MD Deutsches Herzzentrum, Technische Universität, Munich, Germany Abciximab plus Heparin versus Bivalirudin in Patients with NSTEMI Undergoing.
A Prospective, Randomized Comparison of Bivalirudin vs. Heparin Plus Glycoprotein IIb/IIIa Inhibitors During Primary Angioplasty in Acute Myocardial Infarction.
Stent or Surgery: What is Best for a Woman ? Dr R H Stables Cardiothoracic Centre Liverpool UK.
CPORT- E Trial Randomized trial comparing outcomes of non-primary PCI at hospitals with and without on-site cardiac surgery.
B alloon-pump assisted C oronary I ntervention S tudy BCIS-1 Simon Redwood St Thomas’ Hospital / King’s College London On behalf of the BCIS-1 Investigators.
ARMYDA-5 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) Study Prospective, multicenter, randomized trial investigating influence.
TRI vs TFI in STEMI Shenyang Northern Hospital Wang Shouli Han Yalin.
ARMYDA-4 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study Prospective, multicenter, randomized, double blind trial investigating.
HORIZONS AMI Trial H armonizing O utcomes with R evascular IZ ati ON and S tents In A cute M ycoardial I nfarction H armonizing O utcomes with R evascular.
Advanced Angioplasty 2006 Trial Update 2 Other Trials Alun Harcombe from 1 April: Nottingham University Hospitals NHS Trust NO CONFLICT OF INTEREST TO.
Bleeding in Patients Undergoing Percutaneous Coronary Interventions: A Risk Model From 302,152 Patients in the NCDR. Sameer K. Mehta MD, Andrew D. Frutkin.
Do Tirofiban And ReoPro Give Similar Efficacy Outcomes Trial Presented at AHA Scientific Sessions Nov. 15, 2000.
Presenter Disclosure Information DISCLOSURE INFORMATION: The following relationships exist related to this presentation Stock options None; Consults for.
Name of the speaker: Germano DiSciascio I have the following potential conflicts of interest to report:  Consulting  Employment in industry  Stockholder.
STATINS PRE-PCI: A Prospective, Randomized Trial of Statins Prior to Stent Implantation in Patients with Stable Angina Josef VESELKA CardioVascular Center.
Ramin Ebrahimi, MD University of California Los Angeles/ Greater Los Angeles VA Medical Center Implications of Preoperative Thienopyridine Use Prior to.
Name of the speaker: Germano DiSciascio I have the following potential conflicts of interest to report:  Consulting  Employment in industry  Stockholder.
AB 1/03 Non-Coronary Intervention Circulatory Support Advanced Angioplasty 2003 Andreas Baumbach Bristol Royal Infirmary.
Is the Decision-Making after Failure of CTO Angioplasty Same? Infarct Related CTO or Non- Infarct Related CTO (Continue the Procedure in Other Vessel or.
ADMIRALADMIRAL Abciximab before Direct Angioplasty and Stenting in Myocardial Infarction Regarding Acute and Long term follow-up ADMIRAL Study ADMIRAL.
FRagmin® and Fast Revascularization during InStablity in Coronary artery disease FRISC II.
Name of the speaker: Germano DiSciascio I have the following potential conflicts of interest to report:  Consulting  Employment in industry  Stockholder.
Effect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial Myeong-Ki.
IABP用于高危PCI有价值吗? Is IABP Valuable for High-Risk PCI?
Allen Jeremias, Neal Kleiman, Deborah Nassif, Wen-Hua Hsieh, Michael Pencina, Kelly Maresh, Manish Parikh, Donald Cutlip, Ron Waksman, Steven Goldberg,
ISAR-CABG Objective To compare the efficacy of DES with BMS in a randomized trial powered for clinical events Sample 610 patients with de novo SVG lesions.
ARMYDA-4 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study Prospective, multicenter, randomized, double blind trial investigating.
The SAFER Trial Evaluation of the Clinical Safety and Efficacy of the PercuSurge GuardWire in Saphenous Vein Graft Intervention As presented at TCT 2000.
Date of download: 5/30/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Elective Intra-aortic Balloon Counterpulsation During.
Randomized Early versus Late AbciXimab in Acute Myocardial Infarction treated with primary coronary intervention (RELAx-AMI Trial) Mauro Maioli M.D., Francesco.
Duration Safety and Efficacy of Bivalirudin in patients undergoing PCI: The impact of duration of infusion in ACUITY trial Dr. David Cox Lehigh Valley.
Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.
Cardioprotective Effects of Postconditioning in Patients Treated with Primary PCI Evaluated with Magnetic Resonance Jacob T Lønborg Niels Vejlstrup, Erik.
Prof. Dr. Sigmund Silber, FESC, FACC On behalf of the RESOLUTE
The OPTIMAX first-in-man study Mid-term clinical outcome of Titanium-Nitride-Oxide-coated Cobalt Chromium stents in patients with de novo coronary artery.
Debate: Prophylactic Support Increases Risk With Little Benefit
Balloon-pump assisted Coronary Intervention Study (BCIS-1):
Presented by Dr. Leif Thuesen
European Society of Cardiology 2003
3-Year Clinical Outcomes From the RESOLUTE US Study
Impact of clopidogrel loading dose on the safety and effectiveness of bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction:
Orlando, March , American College of Cardiology
Incidence and management of restenosis after treatment of unprotected left main disease with drug-eluting stents: 70 restenotic cases from a cohort of.
What oral antiplatelet therapy would you choose?
Maintenance of Long-Term Clinical Benefit with
DEScover: One-Year Clinical Results
ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions J. Mehilli, MD Deutsches Herzzentrum Technische.
ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions J. Mehilli, MD Deutsches Herzzentrum Technische.
ISAR-LEFT MAIN 2 Randomized Trial Zotarolimus- vs
Atlantic Cardiovascular Patient Outcomes Research Team
ISAR-LEFT MAIN 2 Randomized Trial Zotarolimus- vs
Cardiovascular Epidemiology and Epidemiological Modelling
Presentation transcript:

Balloon-pump assisted Coronary Intervention Study BCIS-1 Simon Redwood Divaka Perera, Rod Stables, Martyn Thomas

Disclosure Statement of Financial Interest This trial was supported by unrestricted grants from: Datascope Eli Lilly Cordis

During High-Risk PCI ACC/AHA 2001 guidelines for PCI, JACC 2001, 37(8)2239 i-lxvi “… reserved only for patients at the extreme end of the spectrum of hemodynamic compromise… … it should be noted that in patients with borderline hemodynamics, ongoing ischemia, or cardiogenic shock, insertion of an intra-aortic balloon just prior to coronary instrumentation has been associated with improved outcomes” ACC/AHA/SCAI Practice Guidelines Update 2005 “ Elective high-risk PCI can be performed safely without IABP or CPS in most circumstances …. Emergency high-risk PCI such as primary PCI can usually be performed without IABP or CPS…” Current Indications for IABP

Current IABP use : Benchmark Registry Stone et al 2003, JACC 41(11) Cardiogenic Shock 27% CABG 17% VSD / MR 12% Angina / LVF / VT 16% High Risk PCI Non Shock 28%

Elective vs provisional IABP in high-risk PCI 133 pts EF <30, elective PCI Group A: elective IABP, 61 pts. JS Group B: Provisional IABP, 72 pts. JS (p=0.008) Jeopardy score: coronary tree divided into 6 segments: LAD, D1, Cx, OM, RCA, PDA. 2 points for each lesion + 2 for each vessel distal to lesion Elective IABP Conventional PCI P value EF Jeopardy score Type B2/C 87% 64% Severe ↓BP or shock 0% 15% Procedural MACE 0% 17% Correlates of procedural events Odds ratio Elective IABP0.11 ( ) Jeopardy score5.37 ( )0.040 Female sex2.72 ( ) Briguori et al, AHJ 2003;145:700-7

IABP Use in High-Risk PCI N = 114 Elective PCI Non-Randomized 68 Prophylactic 48 Rescue IABP P<0.001 P = 0.02 Mishra et al, Am J Cardiol 2006

Objectives: To compare the efficacy and safety of elective Intra-Aortic Balloon Pump (IABP) insertion prior to high-risk PCI vs. conventional treatment (with no planned IABP use) Structure: Prospective, open, randomised trial UK centres + 4 Polish centres n=300 (150 in each arm) Predicted MACE of 5% v 15%, 274 pts 80% power, sign 5% B alloon-pump assisted C oronary I ntervention S tudy

Primary Outcome Measure Major Adverse Cardiovascular Events at hospital discharge or 28 days (whichever is sooner), including All-Cause Death Acute MI (CKMB > 3xULN) Further revascularization by PCI or CABG CVA BCIS-1

Secondary Outcome Measures 1. Six month mortality 2. Procedural Complications VT/VF requiring cardioversion cardiac arrest requiring CPR/ventilation prolonged hypotension (including IABP insertion in “No planned IABP” group) 3. Procedural success 4. Bleeding complications 5. Vascular complications 6. Duration of hospital stay

Inclusion Criteria 1.Impaired LV function (EF<30%) 2.Extensive Myocardium at Risk LMS lesion Jeopardy Score > 8 Exclusion Criteria Cardiogenic Shock Acute STEMI within preceding 48hours VSD, MR or intractable VT/VF Contraindications to IABP insertion

Jeopardy Score Coronary tree divided into 6 segments: LAD, D1, Cx, OM, RCA, PDA. 2 points for each lesion + 2 for each vessel distal to lesion

Distribution of BCIS-1 20 UK Centres

BCIS-1 Polish Centres National Co- ordinator Dr Pawel Buszman 0

BCIS-1 Recruitment Completed 21 st Jan 09 Total 301 patients

Baseline Characteristics n = 260 % Age mean (sd) 70.8 (9.5) Male20980 Diabetic9235 Prior MI Elective12247 Urgent / Emerg13854

Inclusion Criteria Ejection Fraction (Mean + SD) JeopardyN=247%

Procedural Details Lesions per patient (mean)2.1 N% DES only370- BMS only141- DES & BMS9- GP 2b3a10540

Unajudicated Clinical Events to Discharge/ 28 days n = 260% Death31.2 CVA20.8 MI24/ PCI31.2 CABG10.4 Minor Bleed 2-4g Major Bleed > 4g41.5 LOS Median 2 days

Summary The exact role of haemodynamic support for high-risk PCI is unclear BCIS have designed and completed the first randomised trial of elective vs ‘bailout’ IABP in patients with poor LV function and severe coronary disease Full trial results due Q3 2009

Definition of Myocardial Infarction In BCIS-1 CKMB ≥ 3 X ULN. No ECG changes or symptoms are required Patients with admission MI CKMB ≥ 50% of pre-procedure value Patients with MI 24 hrs after CABG either a) the CKMB value ≥ 5 X ULN and new Q waves b) CKMB ≥10 X ULN (with or without Q waves), no symptoms are required Patients who die but no cardiac markers are available Presence of new ST segment elevation and new chest pain For all other circumstances, standard ESC/AHA definitions apply